JonesTrading Thinks Monopar Therapeutics Inc’s Stock is Going to Recover

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Monopar Therapeutics Inc (MNPRResearch Report). The company’s shares closed last Friday at $7.10, close to its 52-week low of $4.94.

According to, Roy is a 5-star analyst with an average return of 32.5% and a 50.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Monopar Therapeutics Inc is a Moderate Buy with an average price target of $42.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.00 and a one-year low of $4.94. Currently, Monopar Therapeutics Inc has an average volume of 11.85K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.